CellBion Jumps Over 10% on Expanded Combo Trial With Keytruda [K-Bio Pulse]
[Kim Jinsoo, Edaily Reporter] Radiopharmaceutical developer CellBion surged more than 10% after news broke that its combination trial with Merck’s Keytruda would be expanded.
Meanwhile, HLB Therapeutics, which dropped last week following a failed FDA approval, rebounded as investors looked ahead to data from an ophthalmology drug trial.
ABL Bio, on the other hand, saw a slight decline as the release of clinical data for its out-licensed second-line cholangiocarcinoma treatment was delayed.
뉴스픽의 주요 문장 추출 기술을 사용하여 “이데일리” 기사 내용을 3줄로 요약한 결과입니다. 일부 누락된 내용이 있어 전반적인 이해를 위해서는 본문 전체 읽기를 권장합니다.
